Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Dicerna Pharmaceutic (NQ: DRNA )

26.98 USD -1.33 (-4.70%)
Official Closing Price Updated: 5:22 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Dicerna Pharmaceutic

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Dicerna Pharmaceuticals Inc (DRNA) Q4 2020 Earnings Call Transcript
DRNA earnings call for the period ending December 31, 2020. 
Tags Market News DRNA
From Motley Fool
The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags IBB ASMB NTRA
From Benzinga
IBD Rating Upgrades: Dicerna Pharmaceuticals Shows Improved Technical Strength
A Relative Strength Rating upgrade for Dicerna Pharmaceuticals shows improving technical performance. Will it continue? 
From Investor's Business Daily
Recap: Dicerna Pharmaceuticals Q4 Earnings
Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) were flat in after-market trading after the company reported Q4 results. Quarterly ... 
Tags BZI/Recaps Market News DRNA
From Benzinga
Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update
Dicerna today reported its financial results for the full year ended Dec. 31, 2020 and provided a corporate update. 
From Business Wire News Releases
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags PRVB NTLA CLNN
From Benzinga
Analysts Expect PBE Will Reach $85
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before ... 
Tags Biotech JNCE UTHR
From Benzinga
Dicerna to Participate in Upcoming Investor Conferences
Dicerna announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences. 
From Business Wire News Releases
Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021
Dicerna will release its fourth quarter and full year 2020 financial results after market close on Thursday, Feb. 25, 2021. 
From Business Wire News Releases
Dicerna Starts Dosing With Nedosiran In Primary Hyperoxaluria Early-Stage Study
Dicerna Pharmaceuticals Inc(NASDAQ:DRNA) initiatespatient dosinginPhase 1 PHYOX 4 trialevaluating ... 
Tags Market News DRNA Biotech
From Benzinga
Dicerna Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3
Dicerna announced initiation of patient dosing in its PHYOX™4 clinical trial to assess nedosiran for the treatment of primary hyperoxaluria type 3. 
From Business Wire News Releases
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags AEZS DRIO IRWD
From Benzinga
Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference
Dicerna announced that Doug Fambrough will participate in two events at the H.C. Wainwright Virtual BioConnect Conference taking place Jan. 11-14. 
From Business Wire News Releases
Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement
Dicerna announced that Novo Nordisk has nominated its first candidate for development under the existing agreement between the two companies. 
From Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna announced the Company approved the grant of inducement stock options of common stock and restricted stock units among three new employees. 
From Business Wire News Releases
Dicerna Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria
Dicerna today announced the enrollment completion of the PHYOX™2 pivotal trial of nedosiran for the treatment of primary hyperoxaluria. 
From Business Wire News Releases
PBE's Holdings Imply 11% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
First Week of DRNA February 2021 Options Trading
Investors in Dicerna Pharmaceuticals Inc (DRNA) saw new options become available this week, for the February 2021 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the... 
Tags Stocks
From Market News Video
Stocks Generating Improved Relative Strength: Dicerna Pharmaceuticals
Dicerna Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
From Investor's Business Daily
Notable Friday Option Activity: MAXR, DRNA, OPCH
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Maxar Technologies Inc (MAXR), where a total volume of 5,451 contracts has been... 
Tags Stocks
From Market News Video
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among six new employees. 
From Business Wire News Releases
Dicerna Pharmaceuticals Trying To Close In On Key Technical Benchmark
Dicerna Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
From Investor's Business Daily
Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting® Digital Experience™ 2020
Dicerna announced positive updated Phase 1 data on its investigational GalXC™ RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV). 
From Business Wire News Releases
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement
Dicerna announced FDA acceptance of the IND Application filed by Lilly for LY3561774, clinical-stage candidate to emerge from their collaboration. 
From Business Wire News Releases
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market. The ... 
Tags KTRA MYL PAVM
From Benzinga
Analysts Anticipate ESML Will Reach $33
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Dicerna to Participate in Upcoming Investor Conferences
Dicerna announced that Douglas M. Fambrough, Ph.D., president and CEO, will be participating in fireside chats at two upcoming investor conferences. 
From Business Wire News Releases
Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020
Dicerna will present an update on the Company’s early-stage development of extrahepatic RNAi therapeutics at TIDES Europe 2020. 
From Business Wire News Releases
Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update
Dicerna today reported its financial results for the third quarter ended Sep. 30, 2020. 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account